/NERV
NERV Stock - Minerva Neurosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$4.04+4.39%
+$0.17 (+4.39%) • Dec 19
86
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.89
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).98
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+23.8%upside
Target: $5.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NERV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.00 – $4.08
TARGET (TP)$5.00
STOP LOSS$3.72
RISK/REWARD1:3.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.41
52W High$12.46
52W Low$1.15
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $41.18M |
| Gross Profit | N/A | N/A | N/A | N/A | $41.18M |
| Gross Margin | N/A | N/A | N/A | N/A | 100.0% |
| Operating Income | $-21,848,386 | $-23,119,576 | $-25,231,326 | $-45,365,657 | $1.85M |
| Net Income | $1.44M | $-30,005,353 | $-32,108,676 | $-49,905,952 | $1.94M |
| Net Margin | N/A | N/A | N/A | N/A | 4.7% |
| EPS | $0.19 | $-4.61 | $-6.01 | $-9.35 | $0.38 |
Company Overview
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
NERVBeat Rate
56%
Last 18 quarters
Avg Surprise
+19.1%
EPS vs Estimate
Beats / Misses
10/7
1 met exactly
Latest EPS
$-0.36
Q4 2025
EPS Surprise History
Q1 24
-35.2%
$-1.19vs$-0.88
Q2 24
+5.8%
$-1.13vs$-1.20
Q3 24
-12.4%
$-1.09vs$-0.97
Q4 24
+394.1%
$2.97vs$-1.01
Q1 25
+46.7%
$-0.56vs$-1.05
Q2 25
+53.3%
$-0.50vs$-1.07
Q3 25
+54.7%
$-0.43vs$-0.95
Q4 25
-2.9%
$-0.36vs$-0.35
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-0.11 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.35 | $-0.36 | -2.9% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.95 | $-0.43 | +54.7% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-1.07 | $-0.50 | +53.3% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $-1.05 | $-0.56 | +46.7% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-1.01 | $2.97 | +394.1% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.97 | $-1.09 | -12.4% | ✗ MISS |
Q2 2024 | May 1, 2024 | $-1.20 | $-1.13 | +5.8% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.88 | $-1.19 | -35.2% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.77 | $-1.03 | -33.8% | ✗ MISS |
Q3 2023 | Aug 1, 2023 | $-0.44 | $-1.12 | -154.5% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-1.63 | $-1.31 | +19.6% | ✓ BEAT |
Q1 2023 | Mar 8, 2023 | $-1.35 | $-1.26 | +6.7% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-1.46 | $-1.29 | +11.6% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-1.84 | $-1.63 | +11.4% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-1.60 | $-1.84 | -15.0% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-1.60 | $-0.96 | +40.0% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-1.76 | $-1.76 | 0.0% | = MET |
Q3 2021 | Aug 2, 2021 | $-1.36 | $-2.00 | -47.1% | ✗ MISS |
Latest News
HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $4
➖ NeutralBenzinga•Nov 6, 2025, 11:58 AM
Minerva Neurosciences Q3 EPS $(0.36) Misses $(0.35) Estimate
📉 NegativeBenzinga•Nov 5, 2025, 12:34 PM
Minerva Neurosciences rises on financing of up to $200M to advance Schizophrenia drug
📈 PositiveSeeking Alpha•Oct 21, 2025, 12:32 PM
Minerva Neurosciences shares are trading higher after the company announced financing of up to $200 million to advance Roluperidone for schizophrenia.
📈 PositiveBenzinga•Oct 21, 2025, 12:03 PM
Minerva Neurosciences Announces Up To $200M In Financing To Advance Roluperidone For Schizophrenia Through Phase 3 Confirmatory Trial And NDA Resubmission
📈 PositiveBenzinga•Oct 21, 2025, 12:02 PM
Frequently Asked Questions about NERV
What is NERV's current stock price?
Minerva Neurosciences, Inc. (NERV) is currently trading at $4.04 per share. The stock has moved +4.39% today.
What is the analyst price target for NERV?
The average analyst price target for NERV is $5.00, based on 1 analyst.
What sector is Minerva Neurosciences, Inc. in?
Minerva Neurosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NERV's market cap?
Minerva Neurosciences, Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does NERV pay dividends?
No, Minerva Neurosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLGN
CollPlant Biotechnologies Ltd.
$1.52
Mkt Cap: $0.0B
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$7.11
Mkt Cap: $0.0B
ENLV
Enlivex Therapeutics Ltd.
$0.83
Mkt Cap: $0.0B
KLTO
Klotho Neurosciences, Inc.
$0.39
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
NRXS
NeurAxis, Inc.
$3.22
Mkt Cap: $0.0B
RLYB
Rallybio Corporation
$0.79
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
TAOX
TAO Synergies Inc.
$5.03
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to NERV for comparison